BioAge Labs (BIOA) Gross Margin (2025 - 2026)

BioAge Labs' (BIOA) quarterly Gross Margin came in at 374.06% in Q1 2026, down 15504.0% year-on-year from N/an in Q1 2025, and up 25.9% quarter-over-quarter from 504.84% in Q4 2025.

BioAge Labs (BIOA) Gross Margin (2025 - 2026) Analysis & Trends

BioAge Labs has disclosed Gross Margin across 2 years of filings, most recently posting 374.06% for Q1 2026.

  • Gross Margin for Q1 2026 came in at 374.06%, down 15504.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 461.86% (up 199845.0% YoY), and the FY2025 annual result was 449.74%, changed N/A from the prior year.
  • Gross Margin came in at 374.06% for Q1 2026 at BioAge Labs, up from 504.84% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 219.02% in Q1 2025 to a low of 504.84% in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 49.52%
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 71.66%
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 82.93%
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 49.50%
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 98.31%
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 57.26%
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -293.83%
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 65.25%
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 61.20%
10 BioAge Labs 671.19 Mn 288.00 Mn -10.37 Mn -374.06%

Historic Data

Download Data
DateValue
Mar 31, 2026 -374.06%
Dec 31, 2025 -504.84%
Sep 30, 2025 -496.30%
Jun 30, 2025 -478.57%
Mar 31, 2025 -219.02%